Early access
Sign in
Taking people in SingaporePhase 3

Trastuzumab Deruxtecan with Bevacizumab for HER2-Expressing Ovarian Cancer

Tests trastuzumab deruxtecan with bevacizumab in adults with HER2-expressing advanced ovarian cancer.

Key facts

Who runs it
Daiichi Sankyo
Where
Singapore, SingaporeSee the 2 sitesAlso in 25 other countries, 243 sites
Registry title
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Status
Recruiting
Phase
Phase 3
People taking part
582 people, planned
Started
19 Mar 2025
Expected to end
31 Jan 2032
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Trastuzumab Deruxtecan
  • Bevacizumab
Record updated
28 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult women with newly diagnosed advanced high-grade epithelial ovarian cancer whose tumor shows HER2 expression. It tests trastuzumab deruxtecan with bevacizumab against bevacizumab alone as first maintenance treatment.

Age
18 years or older
Sex
Women only
Disease stage
Newly diagnosed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, FIGO Stage III or IV
Earlier treatment
Newly diagnosed; the trial gives first-line maintenance treatment
Biomarker or test result
The tumor must show HER2 expression (IHC 3+/2+/1+)

Main reasons for not taking part

  • Cancer that is not of epithelial origin
  • Known or suspected harmful BRCA change that makes a person able to take a PARP inhibitor
  • Planned PARP inhibitor as maintenance treatment
  • Stroke, transient ischemic attack or brain-surface bleeding in the 6 months before randomization
  • Bleeding disorder or significant clotting problem, or a history of bleeding disorders

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Sign and date the tissue prescreening informed consent form (ICF), prior to HER2 central testing. Sign and date the Main ICF prior to the start of any trial- specific qualification procedures. Consent to optional PGx prior to any PGx procedures; *For participants in the safety run-in phase, a safety run-in ICF needs to be signed and dated prior to the start of any trial-specific qualification procedures
  • Adults ≥18 years of age on the day of signing the ICF. Follow local regulatory requirements if the legal age of consent for trial participation is >18 years old
  • Has histologically confirmed diagnosis of epithelial high-grade ovarian, fallopian tube, or primary peritoneal carcinoma per local assessment (including but not limiting to serous, endometrioid, clear cell, carcinosarcoma, mucinous)
  • Is newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV
  • Has HER2 expression

Who cannot take part

  • Has a known or suspected deleterious BRCA alteration as per local test that makes the participant eligible for poly (ADP-ribose) polymerase (PARP) inhibitor
  • Participant to receive PARP inhibitor as maintenance per standard of care and investigator discretion
  • Previous cerebral-vascular accident, transient ischemic attack or subarachnoid hemorrhage within 6 months prior to randomization; *Note: For participants enrolled from the Republic of Korea, country-specific requirements are applicable
  • Has ovarian, fallopian tube, or peritoneal cancer of non-epithelial origin
  • Has evidence of bleeding diathesis or significant coagulopathy (in the absence of anticoagulation therapy)
  • Has a history of hemorrhagic disorders

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Have you ever been told you have ovarian, fallopian tube or peritoneal cancer?
  • Which best describes your most recent course of platinum chemotherapy (such as carboplatin or cisplatin)?
  • Have your doctors told you that your cancer is advanced (stage 3 or 4)? This means it has spread beyond the ovaries to other parts of the belly or the body, even if it was later removed by surgery.
  • What type of ovarian cancer do you have?

Where in Singapore

Also in 25 other countries, 243 sites

  • National Cancer Centre SingaporeSingapore, SingaporeTaking people
  • National University HospitalSingapore, SingaporeTaking people

About the trial

What the trial wants to find out

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.

The 2 groups in the trial

  • Treatment Arm ATreatment being tested

    Participants will receive T-DXd in combination with bevacizumab.

    Treatment: Trastuzumab Deruxtecan and Bevacizumab

  • Treatment Arm BExisting treatment, for comparison

    Participants will receive bevacizumab monotherapy.

    Treatment: Bevacizumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13)
Plain-language title
Trastuzumab Deruxtecan with Bevacizumab for HER2-Expressing Ovarian CancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06819007, who can take part
Record updated
28 October 2026